1. Aspirin inhibits platelet aggregation by inhibiting the action of thromboxane A 2. 2. This isomerization mechanism shows prostaglandin H2 being converted to thromboxane . 3. Thromboxane A2 ( TX2 ) has a positive feedback in platelet activation.4. Receptors that mediate TXA2 actions are thromboxane A2 receptors. 5. The prototype for these drugs is aspirin, which inhibits the production of thromboxane . 6. Picotamide has activity both as a thromboxane synthase inhibitor and as a thromboxane receptor antagonist. 7. Picotamide has activity both as a thromboxane synthase inhibitor and as a thromboxane receptor antagonist. 8. Thromboxane A ( TXA ) is derived from the prostaglandin H2 ( PGH2 ) molecule.9. An olive oil fraction containing DHPE can inhibit platelet aggregation and thromboxane B2 formation in vitro. 10. Thromboxane A2 is also a known vasoconstrictor and is especially important during tissue injury and inflammation.
Mobile